Bispecific binding agents
US-9133272-B2 · Sep 15, 2015 · US
Inhibitory polypeptides specific to WNT inhibitors
US9708375B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9708375-B2 |
| Application number | US-201414776917-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising a non-naturally-occurring monomer domain capable of binding sclerostin, wherein the monomer domain comprises the amino acid sequence of DVAYAECMDSLEDVDYNCFLPEDQ (SEQ ID NO: 683). 2. The polypeptide according to claim 1 , with an affinity (K D ) to sclerostin of less than or equal to 1×10 −7 M. 3. The polypeptide according to claim 1 comprising a dimer of the monomer domain. 4. The polypeptide of claim 1 , further comprising a polypeptide having affinity to DKK1selected from Tables 16-19. 5. The polypeptide of any one of claims 1 , 2 , 3 , and 4 , further comprising a polyethylene glycol (PEG) conjugation or fusion. 6. A peptide fusion comprising a polypeptide comprising a non-naturally-occurring monomer domain capable of binding sclerostin fused to an antibody or fragment thereof, wherein the monomer domain comprises the amino acid sequence DVAYAECMDSLEDVDYNCFLPEDQ (SEQ ID NO: 683). 7. The peptide fusion claim 6 , wherein the polypeptide is fused to the heavy chain or the light chain of the antibody. 8. The peptide fusion of claim 6 , wherein the polypeptide comprises a dimer of the monomer domain. 9. The peptide fusion of claim 7 , 6 or 8 , wherein the polypeptide is fused to a human Fc. 10. The peptide fusion of claim 7 , 6 or 8 , wherein the antibody is an anti-DKK antibody.
Assignees
Inventors
Classifications
- C07K14/51Primary
Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title
Human Necessities · mapped topic
- C07K14/435Primary
from animals; from humans · CPC title
against material from animals or humans · CPC title
fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9708375B2 cover?
- The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/51. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).